Company · Public · CDXC
ChromaDex
Consumer-facing NAD+ precursor business with an associated clinical research programme.
EvidenceEarlyMixed trial endpoints
Listing
Public
Ticker
CDXC
Headquarters
Los Angeles, US
Founded
1999
Technology
Nicotinamide riboside (consumer NAD+)
Category
Market cap
$0.5B
Longevity thesis
Consumer revenue funds evidence generation, but the two must be judged separately.
Pipeline
| Programme | Stage | Focus |
|---|---|---|
| Nicotinamide riboside trials | Investigator-led | Muscle and cardiometabolic endpoints |
Recent developments
- 1 Aug 2026Third-party trial reported mixed endpoints for NR supplementation.
Scientific evidence
EvidenceEarly
Trials are frequently small, short and inconsistently powered.
LONGEFI analysis
Revenue is real; the longevity claim is not yet supported by strong human outcome data. LONGEFI treats mixed readouts here as expected, not surprising.
Analysis is research commentary. It is not investment advice or a recommendation.